Edward Loftus @EdwardLoftus2 Twitter profile

Last Seen Profiles

@parscdotpng

@jandakembangstw

@KyngcsfWiley

@ngentot_stw

@almtlqah

@imghkmn

@DiamondEyez28

@bokeplokalmalam

@parkerk1915444

@excell305

@Gemoy6968

@Thrive_law

@JolvaneB

@acidchrist999

@penyukastw21

@Tantedesijanda

@stwmaniax

@fahad34779

@BinorRaja

@devende56509092

@bokeplokalmalam

@ShreyakSharma

@bootyslime

@Sammy_marie07

@dea_semok

@ahmedmona111111

@bokeplokalmalam

@thomasc6931344

@Bangjon80

@mbelluccisource

@marcos_tropus

@TheHardH

@FredrickaG24313

@TheWeissLab

@bokeplokalmalam

@Yuzu_Neko0101

Edward Loftus

@EdwardLoftus2

2 years

Prof Sandborn getting standing ovation at what is probably his last academic talk! Legend for 30 years #DDW2022

6

16

156

Edward Loftus

@EdwardLoftus2

1 year

This one won a presidential poster because reading it was effortless #ACG2023 ⁦ @AmCollegeGastro ⁩

14

6

146

Edward Loftus

@EdwardLoftus2

2 years

Summary of cancer risks with #IBD therapies ⁦ @MLongMD ⁩ ⁦ @AmerGastroAssn ⁩ ⁦ @CrohnsColitisFn ⁩ #CCCongress23

5

47

132

Edward Loftus

@EdwardLoftus2

2 years

My day is complete #DDW2022 @CrohnsColitisFn

4

10

132

Edward Loftus

@EdwardLoftus2

3 years

Giving a talk to people in Bordeaux at 1 AM in Minnesota #IOIBD ⁦ @IOIBD1 ⁩

11

3

126

Edward Loftus

@EdwardLoftus2

4 years

Clinic at dawn @MayoClinicGIHep there are polyps to snare and mucosa to heal!

8

3

123

Edward Loftus

@EdwardLoftus2

2 years

Last day in clinic for this guy who I have been delighted to work with over the past several years! Proud of you @ManuelBragaMD @MayoClinicGIHep Our loss will be Cleveland’s gain! @IBD_FloMD @MRegueiroMD

4

120

Edward Loftus

@EdwardLoftus2

4 years

Winter is coming @MayoClinic @MayoClinicGIHep

7

6

111

Edward Loftus

@EdwardLoftus2

11 months

Trying to read and score #DDW2024 abstracts. Captions welcomed ⁦ @DDWMeeting ⁩ ⁦ @AmerGastroAssn ⁩

17

4

111

Edward Loftus

@EdwardLoftus2

5 years

Happy Easter from Minnesnowta!!! 🐣🐰

7

1

111

Edward Loftus

@EdwardLoftus2

4 years

Virtual Hawaii vs actual Minnesota #GUILD2021 @GuildConference

7

4

108

Edward Loftus

@EdwardLoftus2

3 years

Somehow sitting at home watching #DDW2021 on laptop in shorts and t shirt isn’t the same as being in San Diego, DC or Chicago @DDWMeeting #wheresthetweetmojo

8

3

107

Edward Loftus

@EdwardLoftus2

4 years

Today is a sad day. Deb and I have worked together for 2 decades. Research and clinical RN extraordinaire. My “secret weapon”! I wish you well in your retirement and I will miss you! (And if u get bored the door is open haha) ⁦⁦ @MayoClinicGIHep ⁩

7

2

103

Edward Loftus

@EdwardLoftus2

2 years

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment ⁦ @SeverineVermei1 ⁩ #MarlaDubinsky ⁦ @AGA_CGH ⁩

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment -...

gov: U-ACHIEVE Induction (NCT02819635) and U-ACCOMPLISH (NCT03653026).

pubmed.ncbi.nlm.nih.gov

2

29

106

Edward Loftus

@EdwardLoftus2

5 years

Obligatory photo #DDW19 #MayoDDW19 Shameless self promotion

3

5

103

Edward Loftus

@EdwardLoftus2

5 years

I liked this poster from the Italian IBD Group - 5 Top Don’ts in IBD #UEGW2019 @my_ueg

3

31

100

Edward Loftus

@EdwardLoftus2

4 years

Now I have figure out how to lose the other “COVID 19” 👍💉💪🤷🏻‍♂️

3

4

101

Edward Loftus

@EdwardLoftus2

2 years

First day back to work in a while… @MayoClinicGIHep grateful for friends and colleagues

16

0

95

Edward Loftus

@EdwardLoftus2

4 months

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease #risankizumab

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it...

finance.yahoo.com

2

25

92

Edward Loftus

@EdwardLoftus2

4 years

Not sure I could present to Dr Fauci—I would be bowing or curtseying and calling him Your Majesty

4

3

90

Edward Loftus

@EdwardLoftus2

2 years

Irritable bowel syndrome: treatment based on pathophysiology and biomarkers - PubMed ⁦ @Gut_BMJ ⁩ ⁦ @MayoClinicGIHep ⁩

Irritable bowel syndrome: treatment based on pathophysiology and biomarkers - PubMed

These advances augur well for the implementation of evidence-based individualised treatment for patients with IBS based on actionable biomarkers or psychological disturbances.

pubmed.ncbi.nlm.nih.gov

1

30

92

Edward Loftus

@EdwardLoftus2

5 years

. @SunandaKaneMD great summary of how to use biologics during pregnancy in #IBD #RealWorldIBD

1

32

89

Edward Loftus

@EdwardLoftus2

3 years

IBD fellows past present and future! @ManuelBragaMD @amjohnsonMD @VictorChedidMD @TharayilVivek @GuiRamosMD #AbhiVasudevan @MayoClinicGIHep (and a good time was had by all)

8

3

87

Edward Loftus

@EdwardLoftus2

5 years

Hey @DDWMeeting we need stickers like this #UEGW2019

4

9

86

Edward Loftus

@EdwardLoftus2

4 years

My summary of short talk on medical de-escalation in #IBD #BigGutIBD @nyulangone @DavidHudesmanMD @FezaRemziMD @shannonchangmd @DrJordanAxelrad @MLongMD

4

24

86

Edward Loftus

@EdwardLoftus2

1 year

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults

3

27

84

Edward Loftus

@EdwardLoftus2

1 year

@drkeithsiau I would use the money to upgrade your monitor

6

1

83

Edward Loftus

@EdwardLoftus2

4 years

December morning ⁦ @MayoClinic ⁩ ⁦ @MayoClinicGIHep ⁩

2

4

81

Edward Loftus

@EdwardLoftus2

7 years

Thought I was going to be the first to post this but I was beaten. Darn you @DanSharpIBD #DDW17

2

6

81

Edward Loftus

@EdwardLoftus2

2 years

No that would be motility #DDW2022

1

4

82

Edward Loftus

@EdwardLoftus2

1 year

Last night was Evening of Hope gala for the MN chapter of @CrohnsColitisFn @CCfdnMinnesota ! Our colleague @LauraRaffalsMD was Physician of the Year! A great event for a great cause! @DarrellPardi @VictorChedidMD @NayantaraCoelho @amjohnsonMD @dr_davidchiang @NavreetChowlaMD

3

5

82

Edward Loftus

@EdwardLoftus2

5 years

No Association Linking Proton Pump Inhibitor Use to Dementia : American Journal of Gastroenterology @AmCollegeGastro

3

27

78

Edward Loftus

@EdwardLoftus2

3 years

Poterucha: more tips for working with fellows in the clinic!!! “Be present” ⁦ @MayoClinicGIHep ⁩

2

7

80

Edward Loftus

@EdwardLoftus2

3 months

Risankizumab for Ulcerative Colitis @JAMA_current @RPanaccione @JeanFredericCo1

Risankizumab for Ulcerative Colitis

These 2 randomized clinical trials compare the efficacy and safety of risankizumab vs placebo during an induction trial and a maintenance trial in patients with ulcerative colitis.

jamanetwork.com

0

28

84

Edward Loftus

@EdwardLoftus2

5 years

Have been doing this all weekend #COVID19

Adi

@IDdocAdi

5 years

Medical professionals internally right now

68

783

3K

5

3

77

Edward Loftus

@EdwardLoftus2

3 months

Presenting to Korea at 5 AM ⁦ @CrnstnsHlth ⁩ ⁦ @IBDMD ⁩ #DDW2024 #IBD

6

0

79

Edward Loftus

@EdwardLoftus2

5 years

Squad #IBD Xcel ⁦ @CrnstnsHlth ⁩ ⁦ @MRegueiroMD ⁩ ⁦ @DrCoreySiegel ⁩ ⁦ @MLongMD ⁩ ⁦ @ibddocmaria ⁩ ⁦ @IBDMD ⁩

4

5

77

Edward Loftus

@EdwardLoftus2

1 year

Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab @AndresYarur @doc_ibd @ibddocmaria @P_DeepakIBDMD @BeniwalPatelMD @AGA_CGH

Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not...

The aim of this study was to assess how 6-thioguanine nucleotide (6-TGN) levels and use of oral methotrexate relate to the pharmacokinetics of biologics.

www.cghjournal.org

2

25

76

Edward Loftus

@EdwardLoftus2

5 months

Received this nice token of appreciation from ⁦ @ClevelandClinic ⁩ for the talk last week! Thank you 🙏 ⁦ @SaraElOualiMD ⁩ ⁦ @IBD_FloMD ⁩ ⁦ @MRegueiroMD ⁩

0

4

77

Edward Loftus

@EdwardLoftus2

4 years

Dose 2 underway...microchips working their magic #FauciOuchie

4

76

Edward Loftus

@EdwardLoftus2

6 months

Backyard in Rochester #Auroraborealis

4

1

76

Edward Loftus

@EdwardLoftus2

4 years

Subcutaneous infliximab-dyyb non-inferior to IV formulation @AGA_Gastro @BDYE_IBD @HealioGastro

Subcutaneous Remsima non-inferior to IV formulation

The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity profiles in patients with inflammatory bowel disease, according to study results.

www.healio.com

1

19

73

Edward Loftus

@EdwardLoftus2

3 years

Ustekinumab in real-world practice: SUCCESS Consortium just presented by @amjohnsonMD #DDW2021 As you might expect, most effective in bio-naive #Crohns

1

30

72

Edward Loftus

@EdwardLoftus2

5 months

Priscila it has been an honor to work with you and we will miss you! @PriSantiagoMD @MayoClinicGIHep @VictorChedidMD

4

2

71

Edward Loftus

@EdwardLoftus2

4 years

Christmas lights...

3

2

70

Edward Loftus

@EdwardLoftus2

2 years

Mucosal healing?

9

1

69

Edward Loftus

@EdwardLoftus2

4 years

Combining different biologics or advanced therapies seems surprisingly safe ⁦ @P_DeepakIBDMD ⁩ #WUIBDCME21

7

18

70

Edward Loftus

@EdwardLoftus2

3 years

Rise and shine @MayoClinicGIHep

2

0

66

Edward Loftus

@EdwardLoftus2

2 years

In this paper we review JAKs including JAK1s, S1P receptor modulators, anti-IL-23s and stem cells @GastroHep @MayoClinicGIHep @PriSantiagoMD @ManuelBragaMD

Gastro Hep

@GastroHep

2 years

“Novel Therapies for Patients With Inflammatory Bowel Disease” by Priscila Santiago, MD, Manuel B. Braga-Neto, MD, PhD, and Edward V. Loftus Jr, MD @PriSantiagoMD @ManuelBragaMD @EdwardLoftus2 @MayoClinic

0

2

25

2

10

69

Edward Loftus

@EdwardLoftus2

8 months

It’s a tough job but someone has to do it

7

0

65

Edward Loftus

@EdwardLoftus2

4 years

We are getting a White Christmas after all!

2

1

67

Edward Loftus

@EdwardLoftus2

1 year

I have been looking forward to this talk at #ACG2023 but I was kind of disappointed to hear he has published only 700 papers ⁦ @AmCollegeGastro ⁩ ⁦ @MLongMD ⁩ ⁦ @JasmohanBajaj ⁩ #AmericanJournalofCharlesBernstein

3

6

65

Edward Loftus

@EdwardLoftus2

2 years

In Memoriam: Emeritus Prof. Dr. Paul Rutgeerts (1948–2020) @AGA_Gastro

In Memoriam: Emeritus Prof. Dr. Paul Rutgeerts (1948–2020)

On September 12, 2020, we learned about the sudden and unexpected passing of Paul Rutgeerts MD, PhD. Paul was born in Brussels, Belgium, in 1948 and obtained his medical degree in 1973 at the...

www.gastrojournal.org

1

17

66

Edward Loftus

@EdwardLoftus2

2 years

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results from the SUCCESS Consortium - PubMed ⁦ @amjohnsonMD ⁩ ⁦ @PDulaiMD ⁩ ⁦ @AmJGastro ⁩

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results...

UST represents a safe and effective treatment option for CD, with 40% of patients from a highly refractory cohort achieving clinical remission by 12 months. The greatest treatment effect of UST was...

pubmed.ncbi.nlm.nih.gov

1

9

65

Edward Loftus

@EdwardLoftus2

4 years

Not all diarrhea is due to #IBD even in #IBD patients...for example we see a lot of SIBO, bile acid malabsorption, partial short bowel, and occasionally pancreatic insufficiency

Keith Siau

@drkeithsiau

4 years

Causes of chronic diarrhoea with a normal colonoscopy 🔦 #MedTwitter

20

189

596

1

16

62

Edward Loftus

@EdwardLoftus2

1 year

Has to be a better way…. #DDW23

9

0

64

Edward Loftus

@EdwardLoftus2

2 years

Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis @AGA_CGH @nghia_nguyen_md @ChrisMa_YYC @PDulaiMD @vipuljairath

Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic...

Patients with Crohn’s disease (CD) treated with ustekinumab who experience inadequate response, or loss of response after standard induction and/or maintenance dosing may benefit from dose escalati...

www.cghjournal.org

2

19

63

Edward Loftus

@EdwardLoftus2

3 years

A plea to continue biologic in pregnancy since stopping it increases risk and doesn’t confer benefit #IBD ⁦ @UmaMahadevanIBD ⁩ ⁦ @MayoClinicGIHep ⁩

1

17

63

Edward Loftus

@EdwardLoftus2

1 year

What a great option for #IBD patients! Gives us flexibility in therapeutic options for ulcerative colitis!!!

Florian Rieder

@IBD_FloMD

1 year

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis | Business Wire

2

27

110

1

12

64

Edward Loftus

@EdwardLoftus2

2 years

They're everywhere

4

1

62

Edward Loftus

@EdwardLoftus2

3 years

Double vaxxed, boosted and now omicroned…may you live in interesting times

37

1

62

Edward Loftus

@EdwardLoftus2

4 years

2925 mile journey from Rochester to Visalia via Devils Tower and Death Valley #PandemicLife

5

2

63

Edward Loftus

@EdwardLoftus2

3 years

Vacation

6

0

63

Edward Loftus

@EdwardLoftus2

5 months

US Insurers Out of Step With IBD Treatment Guidelines There's no scientific reason to require #IBD patients to fail 5-ASA or thiopurine/methotrexate monotherapy prior to starting an advanced therapy

US Insurers Out of Step With IBD Treatment Guidelines

Most US insurance companies require patients to fail conventional therapies for Crohn's disease and ulcerative colitis before they will cover a biologic agent, contrary to treatment guidelines.

www.medscape.com

2

18

59

Edward Loftus

@EdwardLoftus2

3 years

Made it #GUILD22 @GuildConference @UmaMahadevanIBD

3

2

62

Edward Loftus

@EdwardLoftus2

5 years

Can my Twitter friends help me here? What is this?

35

5

61

Edward Loftus

@EdwardLoftus2

3 years

Ultra-processed foods, risk for Crohn’s disease #DDW2021

8

18

62

Edward Loftus

@EdwardLoftus2

2 years

Last day in clinic with this guy who I have had privilege to work with over past 4 years @GuiRamosMD Not to fear—he will be back in 2 years! @MayoClinicGIHep

2

1

61

Edward Loftus

@EdwardLoftus2

4 years

The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study ⁦ @GuiRamosMD ⁩ ⁦ @Badr_AlBawardy ⁩ ⁦ @MayoClinicGIHep ⁩ ⁦ @IBDJournals ⁩

The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel...

Almost one-third of patients had worsening EIMs after VDZ, which resulted in VDZ discontinuation in approximately 10% of patients. Previous biologic use or concurrent immunosuppressant or corticost...

pubmed.ncbi.nlm.nih.gov

2

16

59

Edward Loftus

@EdwardLoftus2

3 years

“Glue people”: these are 2 of our secret weapons @MayoClinicGIHep Deb in appt office and Susie my admin asst from time immemorial! Deb is retiring after 44 yrs at @MayoClinic but she is not allowed to retire! #ThankfulThursday

3

1

60

Edward Loftus

@EdwardLoftus2

10 months

Sands summary slide for JAK inhibitors in #IBD @GuildConference @bruce_sands1 #GUILD2024

3

18

59

Edward Loftus

@EdwardLoftus2

3 years

FDA approves upadacitinib for moderate to severe ulcerative colitis @HealioGastro

FDA approves Rinvoq for moderate to severe ulcerative colitis

Biopharmaceutical company AbbVie announced FDA approval for Rinvoq for the treatment of adults with moderately to severely active ulcerative colitis.According to a press release, the approval was...

www.healio.com

2

18

60

Edward Loftus

@EdwardLoftus2

5 months

Mayo stand and deliver! Dr Coelho-Prabyu and I moderated and Dr Ilyas presented at the #DDW2024 combined symposium on #PSC and #IBD ! @NayantaraCoelho @SumeraIlyasMD @MayoClinicGIHep @DDWMeeting @AmerGastroAssn @AASLDtweets

0

5

58

Edward Loftus

@EdwardLoftus2

11 months

Dr Naina Coelho: How to monitor for dysplasia in #IBD Strictures especially in UC should be biopsied. #PSC IBD needs to be watched especially carefully. Still a role for dye spray chromoendoscopy #AIBD2023 @NayantaraCoelho

0

13

58

Edward Loftus

@EdwardLoftus2

2 years

Colectomy Rates in Ulcerative Colitis Unchanged During 40-Year Period

There was no significant difference in colectomy rates during the past 40 years in patients with UC despite use of immunomodulators and biologics.

www.gastroenterologyadvisor.com

2

14

57

Edward Loftus

@EdwardLoftus2

2 years

Actually sunny this afternoon!

6

0

57

Edward Loftus

@EdwardLoftus2

5 years

. @bruce_sands1 : best study of lymphoma risk with #IBD meds comes from 🇫🇷—thiopurines or anti-TNFs essentially double the risk, but absolute risk is low, about 1 in 2000 annually #RealWorldIBD @MayoClinicGIHep

3

18

56

Edward Loftus

@EdwardLoftus2

4 months

Congratulations 🎊🎉🎈🍾 to @PriSantiagoMD and #ManarAskar on completing #IBD fellowship and looking forward to @SiriUrquhartMD and @dunleavy_katie starting!!! Thank you @VictorChedidMD and @amjohnsonMD for coming!

4

3

56

Edward Loftus

@EdwardLoftus2

1 year

Prof U Mahadevan: JAK users guide @UmaMahadevanIBD #DDW2023

1

9

56

Edward Loftus

@EdwardLoftus2

4 years

GI physicians urge COVID-19 vaccines for all IBD patients @IBDConference @ibddocmaria @MRegueiroMD @IBDMD @MichaelKappel12 @IOIBD1

1

22

55

Edward Loftus

@EdwardLoftus2

2 years

Dr Laura Targownik discussing systematic review of combining biologics/advanced therapies in #IBD #CCCongress23 ⁦ @AmerGastroAssn ⁩ ⁦ @CrohnsColitisFn ⁩ ⁦ @P_DeepakIBDMD ⁩

0

11

56

Edward Loftus

@EdwardLoftus2

2 years

What a team #IBDCC ⁦ @DVinsard ⁩ ⁦ @PriSantiagoMD ⁩ ⁦ @MayoClinicGIHep ⁩

2

1

55

Edward Loftus

@EdwardLoftus2

2 years

Honored to meet the great @DrHarryThomas in person at the REACH-IBD event! Thoroughly enjoy his tweets #CCCongress23 @AdamFayeMD @ibdgijami

5

3

55

Edward Loftus

@EdwardLoftus2

2 years

Brainpower #IOIBD @IOIBD1 @UmaMahadevanIBD @ibddocmaria @SeverineVermei1 @annegri50789035 @Iris_Dotan

1

3

55

Edward Loftus

@EdwardLoftus2

5 years

Spoils of battle—won’t be collecting any of these for a while! #COVID19

4

1

56

Edward Loftus

@EdwardLoftus2

5 years

Aloha—From minus 18 to 83 in 12 hours #GUILD2020

3

2

56

Edward Loftus

@EdwardLoftus2

10 months

It’s a tough job but someone has to do it #GUILD2024 come for the sun stay for the #IBD learnings ( and other stuff too) @GuildConference @UmaMahadevanIBD

2

3

55

Edward Loftus

@EdwardLoftus2

3 years

Despite recent European warning it’s safe to continue biologics while breastfeeding ⁦ @UmaMahadevanIBD ⁩ ⁦ @MayoClinicGIHep ⁩

4

15

54

Edward Loftus

@EdwardLoftus2

5 years

Some have Easter egg hunts. Others have snowball fights #Minnesota

4

1

54

Edward Loftus

@EdwardLoftus2

2 years

My bro @Loftus gave a talk at Alice Mayo Society about his book The Messenger (about Moderna’s development of mRNA SARS-CoV2 vaccine) @MayoClinic @HarvardBiz

1

0

55

Edward Loftus

@EdwardLoftus2

3 years

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active...

AbstractBackground and Aims. To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous

academic.oup.com

1

19

54

Edward Loftus

@EdwardLoftus2

2 years

Enjoying my desert colleagues! @MayoClinicGIHep @NeenaSAbrahamMD @JLeightonMD